31 recruiting, 24 unknown, 15 not yet recruiting, 9 active not recruiting. 66 Phase 2, 14 Phase 1, 5 Phase 3, 3 Not applicable, 2 Early Phase 1.
Follow Cadonilimab: new trials by email Literature Review of Cadonilimab trials Research Report on Cadonilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study Larotrectinib, Cadonilimab, Plixorafenib - IDH Wildtype Glioblastoma, Glioblastoma (GBM) | Early Phase 1 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 12 | 2027-03-01 | 2026-10-30 |
| A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer Cadonilimab, Megestrol Acetate (MA), Levonorgestrel-releasing intrauterine system - Endometrial Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 10 | 2026-10-01 | 2026-10-28 |
| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma Cadonilimab, CAPOX regimen, Nivolumab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 900 | 2026-09-24 | 2026-09-29 |
| THIO and Cadonilimab in Resectable Hepatocellular Carcinoma ateganosine, Cadonilimab - Resectable Hepatocellular Carcinoma | Early Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-09-01 | 2026-09-03 |
| A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer Cadonilimab - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 37 | 2026-05-27 | 2026-09-23 |
| Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT Cadonilimab, RT - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Ruijin Hospital | 45 | 2026-03-01 | 2026-03-05 |
| Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Cadonilimab, Capecitabine - Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 75 | 2025-11-28 | 2025-11-24 |
| A Study of Ivonescimab in First-Line ES-SCLC Ivonescimab, Cadonilimab, AK117 - Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Akeso | 180 | 2025-10-29 | 2025-11-24 |
| A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma Cadonilimab, SOX chemotherapy, Placebo - Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | Akeso | 760 | 2025-08-14 | 2026-02-11 |
| A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC AK154, Cadonilimab, Ivonescimab (SMT112 or AK112) Injection - Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma | Phase 1 | Not yet recruiting | Akeso | 60 | 2025-07-22 | 2025-04-06 |
| SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab - Advanced Gastric Cancer, Advanced Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Zhang Tao | 26 | 2025-03-20 | 2025-04-27 |
| Ligufalimab and Cadonilimab in Advanced Liver Cancers Ligufalimab, Cadonilimab - Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 64 | 2025-02-18 | 2026-02-27 |
| IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial IN10018, Nab-paclitaxel, Cadonilimab - Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 25 | 2025-02-17 | 2026-01-13 |
| Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC Ivonescimab, Cadonilimab, Etoposide - Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan University | 80 | 2025-02-01 | 2025-01-10 |
| Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Cadonilimab, radiotherapy, carboplatin, paclitaxel - Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages | Not applicable | Enrolling by invitation | First Affiliated Hospital of Ningbo University | 20 | 2024-12-01 | 2025-03-25 |
| An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer AK104, AK112, Chemotherapy - Recurrent Ovarian Cancer | Phase 2 | Recruiting | Akeso | 172 | 2024-11-12 | 2025-03-12 |
| A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma Cadonilimab, Adriamycin - Advanced Soft-tissue Sarcoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 53 | 2024-10-09 | 2025-07-18 |
| A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) AK112, Cadonilimab, AK127 - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Akeso | 280 | 2024-09-24 | 2026-03-04 |
| Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer Cadonilimab - Cervical Cancer | Recruiting | Fujian Cancer Hospital | 200 | 2024-09-07 | 2024-09-19 | |
| Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer Cadonilimab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 50 | 2024-09-03 | 2024-09-19 |
Showing 20 of 82. Sign in to see all of them.
Carcinoma, Hepatocellular (8) · Uterine Cervical Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (5) · Diabetes Mellitus, Insulin-Dependent, 12 (4) · Endometrial Neoplasms (4) · Nasopharyngeal Carcinoma (4) · Stomach Neoplasms (4) · Esophageal Squamous Cell Carcinoma (3) · Small Cell Lung Carcinoma (3) · Glioblastoma (2) · Liver Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Recurrence (2)
Akeso (9) · Sun Yat-sen University (8) · Fujian Cancer Hospital (4) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Guangzhou Institute of Respiratory Disease (2) · Hunan Cancer Hospital (2) · Peking University Cancer Hospital & Institute (2) · Peking University Third Hospital (2) · Sichuan University (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Tongji Hospital (2) · University of Texas Southwestern Medical Center (2) · Chinese Academy of Medical Sciences (1)
China (60) · United States (5) · Australia (1) · Germany (1) · Poland (1)
Lin Shen, MD (2) · Amir Jazaeri (1) · Anwen Liu, PhD (1) · Baohui Han, M.D (1) · Chong Zhao, MD, PhD (1) · Chunxia Su, Phd (1) · David Hsieh, MD (1) · Ding Ma (1) · Ge Lou, PHD (1) · Guoxin Li, M.D., Ph.D (1) · Han Dr. Gao (1) · Hongqing Zhuang, M.D. (1) · Hu Ma, Ph.D (1) · Hui Gan, MBBS, FRACP (1) · Hui Qiu, Ph.D. (1)
PMID 28837405, PMID 29584545, PMID 31150573, PMID 35108470, PMID 35986837, PMID 36990609, PMID 37797632, PMID 37852261, PMID 38706247, PMID 40389320, PMID 40693391, PMID 40705040, PMID 40726978, PMID 41167638, PMID 41293180, PMID 41582028, PMID 42000370, PMID 42682622, PMID 42838953